nach oben

01.12.2018 | Review | Ausgabe 1/2018 Open Access

The perfect personalized cancer therapy: cancer vaccines against neoantigens

Zeitschrift:: Journal of Experimental & Clinical Cancer Research > Ausgabe 1/2018

Autoren:: Luigi Aurisicchio, Matteo Pallocca, Gennaro Ciliberto, Fabio Palombo

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Luigi Aurisicchio and Matteo Pallocca contributed equally.

Gennaro Ciliberto and Fabio Palombo contributed equally.

Abstract

In the advent of Immune Checkpoint inhibitors (ICI) and of CAR-T adoptive T-cells, the new frontier in Oncology is Cancer Immunotherapy because of its ability to provide long term clinical benefit in metastatic disease in several solid and liquid tumor types. It is now clear that ICI acts by unmasking preexisting immune responses as well as by inducing de novo responses against tumor neoantigens. Thanks to theprogress made in genomics technologies and the evolution of bioinformatics, neoantigens represent ideal targets, due to their specific expression in cancer tissue and the potential lack of side effects. In this review, we discuss the promise of preclinical and clinical results with mutation-derived neoantigen cancer vaccines (NCVs) along with the current limitations from bioinformatics prediction to manufacturing an effective new therapeutic approach.

Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017;7:264–76. CrossRefPubMed

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. https://doi.org/10.1038/nature12477. Epub 2013 Aug 14. Erratum in: Nature. 2013 Oct 10;502(7470):258. Imielinsk, Marcin [corrected to Imielinski, Marcin].

Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, et al. Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell Elsevier Inc. 2016;165:234–46. Available from: http://www.cell.com/cell/fulltext/S0092-8674(16)30059-9

Seliger B, Kloor M, Ferrone S. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncoimmunology. 2017;6(2):e1171447. https://doi.org/10.1080/2162402X.2016.1171447.

Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Publ. Gr. Nature Publishing Group; 2017; Available from: https://doi.org/10.1038/nri.2017.131

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer England. 2017;17:209–22. CrossRef

Finn OJ, Rammensee H-G. Is it possible to develop Cancer vaccines to Neoantigens, what are the major challenges, and how can these be overcome? United States: Neoantigens: Nothing New in Spite of the Name. Cold Spring Harb. Perspect. Biol; 2017.

Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24:743–50. CrossRefPubMedPubMedCentral

Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep The Authors. 2016;15:857–65. Available from: https://doi.org/10.1016/j.celrep.2016.03.075 CrossRef

10.

Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319–23. CrossRefPubMed

11.

Tran E, Robbins PF, Rosenberg SA. Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017;18:255–62. CrossRefPubMed

12.

Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res. 2016;22:1845–55. CrossRefPubMedPubMedCentral

13.

Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (80-. ). 2015;350:207–11. [cited 2018 Jan 30]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26359337 CrossRef

14.

Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (80-. ). 2015;348:124–128. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25765070%5Cn, http://www.sciencemag.org/cgi/doi/10.1126/science.aaa1348

15.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;6733:1–11. Available from: http://science.sciencemag.org/content/sci/early/2017/06/07/science.aan6733.full.pdf%5Cn, http://www.ncbi.nlm.nih.gov/pubmed/28596308

16.

McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (80-. ). 2016;351:1463–9. CrossRefPubMedCentral

17.

Strønen E, Toebes M, Kelderman S, Van BMM, Yang W, Van RN, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science (80-. ). 2016;2288:1–11.

18.

Tran E, Turcotte S, Gros A, Robbins PF, Lu Y, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial Cancer. Science (80- ). 2014;9:641–5. CrossRef

19.

Robbins PF, Lu Y-C, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747–752. Available from: http://www.nature.com/nm/journal/v19/n6/full/nm.3161.html#methods%5Cn, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3757932&tool=pmcentrez&rendertype=abstract

20.

Castle JC, Kreiter S, Diekmann J, Löwer M, Van De Roemer N, De Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72:1081–91. CrossRefPubMed

21.

Liu XS, Mardis ER. Applications of Immunogenomics to Cancer. Cell. 2017;168:600–12. CrossRefPubMed

22.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015;520:692–696. Available from: http://www.nature.com/doifinder/10.1038/nature14426%5Cn, /link?doi=10.1038/nature14426

23.

Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515:572–576. Available from: http://www.nature.com/doifinder/10.1038/nature14001%5Cn, http://www.ncbi.nlm.nih.gov/pubmed/25428506

24.

Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater England. 2017;16:489–96. CrossRef

25.

Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli S a, Pawashe AP, et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 2014;211:2231–2248. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4203949&tool=pmcentrez&rendertype=abstract%5Cn, http://www.ncbi.nlm.nih.gov/pubmed/25245761%5Cn, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4203949

26.

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature [Internet]. 2014;515:577–81. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4279952&tool=pmcentrez&rendertype=abstract.

27.

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014;512:324–327. Available from: http://www.nature.com/doifinder/10.1038/nature13387%5Cn, http://www.ncbi.nlm.nih.gov/pubmed/25043048%5Cn, http://www.nature.com/doifinder/10.1038/nature13387

28.

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396–401. CrossRefPubMed

29.

Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Cancer immunotherapy; 2016. p. 1.

30.

Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, et al. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS One. 2016;11:1–22. Available from: https://doi.org/10.1371/journal.pone.0155189

31.

Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Johanns T, Alexandrov A, et al. Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. Oncotarget. 2018;9(3):4109–4119. https://doi.org/10.18632/oncotarget.23751

32.

Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, Lee CW, Kim S, Woo JW, Park KS, Hwang YY, Park J, Lee IH, Lim KT, Lee KH, Jeong MS, Surh CD, Suh YS, Park JS, Sung YC. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317. https://doi.org/10.1038/ncomms6317. PMID:25354725

33.

Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078–88. CrossRefPubMedPubMedCentral

34.

Morrow MP, Kraynyak KA, Sylvester AJ, Dallas M, Knoblock D, Boyer JD, et al. Clinical and immunologic biomarkers for histologic regression of high-grade cervical dysplasia and clearance of HPV16 and HPV18 after immunotherapy. Clin Cancer Res. 2018;24:276–94. CrossRefPubMed

35.

Diaz-Montero CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med. 2013;11:1. Available from: Journal of Translational Medicine CrossRef

36.

Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (80-. ). 2015;348:803–8. Available from: http://www.sciencemag.org/content/348/6236/803.full CrossRef

37.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217–21. Nature Publishing Group Available from: https://doi.org/10.1038/nature22991 CrossRefPubMedPubMedCentral

38.

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222–6. Nature Publishing Group Available from: https://doi.org/10.1038/nature23003

39.

Castel SE, Levy-Moonshine A, Mohammadi P, Banks E, Lappalainen T. Tools and best practices for data processing in allelic expression analysis. Genome Biol. 2015;16:195. [cited 2018 Feb 11]Available from: http://genomebiology.com/2015/16/1/195 CrossRefPubMedPubMedCentral

40.

Boegel S, Löwer M, Schäfer M, Bukur T, de Graaf J, Boisguérin V, et al. HLA typing from RNA-Seq sequence reads. Genome Med. 2012;4:102. [cited 2018 Feb 11]Available from: http://genomemedicine.biomedcentral.com/articles/10.1186/gm403 CrossRefPubMedPubMedCentral

41.

Warren RL, Choe G, Freeman DJ, Castellarin M, Munro S, Moore R, et al. Derivation of HLA types from shotgun sequence datasets. Genome Med. 2012;4:95. [cited 2018 Feb 11] Available from: http://genomemedicine.biomedcentral.com/articles/10.1186/gm396 CrossRefPubMedPubMedCentral

42.

Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33:1152–8. [cited 2018 Feb 11] Available from: http://www.nature.com/articles/nbt.3344 CrossRefPubMedPubMedCentral

43.

Tang S, Madhavan S. neoantigenR: an annotation based pipeline for tumor neoantigen identification from sequencing data. bioRxiv. 2017; Available from: http://biorxiv.org/content/early/2017/08/08/171843.abstract

44.

Bhasin M, Raghava GPS. Analysis and prediction of affinity of TAP binding peptides using cascade SVM. Protein Sci. 2004;13:596–607. Cold Spring Harbor Laboratory Press Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2286721/ CrossRefPubMedPubMedCentral

45.

Hearn A, York IA, Rock KL. The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J Immunol. 2009;183:5526–36. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855122/ CrossRefPubMedPubMedCentral

46.

Zhang GL, Petrovsky N, Kwoh CK, August JT, Brusic V. PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing. Immunome res. London: BioMed central. 2006;2:3. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1524936/

47.

Chen H, Li L, Weimershaus M, Evnouchidou I, van Endert P, Bouvier M. ERAP1-ERAP2 dimers trim MHC I-bound precursor peptides; implications for understanding peptide editing. Sci Rep. 2016;6:28902. Nature Publishing Group. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981824/ CrossRefPubMedPubMedCentral

48.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;2189–2199. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25409260.

49.

Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. England. 2017;551:512–6.

50.

Luksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature England. 2017;551:517–20.

51.

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell–mediated immunotherapy. Cancer Discov. 2016;6:202–16. CrossRefPubMed

52.

Rizvi NA, Chan TA. Immunotherapy and oncogenic pathways: the PTEN connection. Cancer Discov. 2016;6:128–9. CrossRefPubMedPubMedCentral

53.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, et al. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Sci Rep. 2017;7:1–15. CrossRef

54.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell Elsevier Inc. 2016;165:35–44.

55.

George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine Leiomyosarcoma. Immunity Elsevier Inc. 2017;46:197–204.

56.

Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167:397–404.e9. CrossRefPubMedPubMedCentral

57.

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer Immunogenomic analyses reveal genotype-Immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep ElsevierCompany. 2017;18:248–62. CrossRef

58.

Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: a focus on pembrolizumab. Cancer Treat Rev. 2018;62:39–49. CrossRefPubMed

59.

Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 2017;8.

60.

Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, et al. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology. United States. 2016;5:e1238557.

61.

Mcgranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (80-. ). 2016;351:1463–9. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.aaf1490 CrossRefPubMedCentral

62.

Strønen E, Toebes M, Kelderman S, Buuren MM Van, Yang W, Rooij N Van, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires(1). 2016;2288:1–11.

63.

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577–81. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4279952&tool=pmcentrez&rendertype=abstract CrossRefPubMedPubMedCentral

64.

Tappeiner E, Finotello F, Charoentong P, Mayer C, Rieder D, Trajanoski Z. TIminer: NGS data mining pipeline for cancer immunology and immunotherapy. Bioinformatics. 2017;33:3140–1. [cited 2018 Feb 11] Available from: http://academic.oup.com/bioinformatics/article/33/19/3140/3868722 CrossRefPubMedPubMedCentral

65.

Bais P, Namburi S, Gatti DM, Zhang X, Chuang JH. CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens. Bioinformatics. 2017;33:3110–2. [cited 2018 Feb 11] Available from: http://academic.oup.com/bioinformatics/article/33/19/3110/3866879/CloudNeo-a-cloud-pipeline-for-identifying CrossRefPubMedPubMedCentral

66.

Zhou Z, Lyu X, Wu J, Yang X, Wu S, Zhou J, et al. TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection. R Soc open Sci. 2017;4:170050. [cited 2018 Feb 11] Available from: http://rsos.royalsocietypublishing.org/lookup/doi/10.1098/rsos.170050 CrossRefPubMedPubMedCentral

67.

Zhang J, Mardis ER, Maher CA. INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery. Bioinformatics England. 2017;33:555–7.

68.

Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, et al. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8:11. [cited 2018 Feb 11] Available from: http://genomemedicine.com/content/8/1/11 CrossRefPubMedPubMedCentral

Titel: The perfect personalized cancer therapy: cancer vaccines against neoantigens
Autoren:: Luigi Aurisicchio
Matteo Pallocca
Gennaro Ciliberto
Fabio Palombo
Publikationsdatum: 01.12.2018
DOI: https://doi.org/10.1186/s13046-018-0751-1
Verlag: BioMed Central
Zeitschrift: Journal of Experimental & Clinical Cancer Research
Ausgabe 1/2018
Elektronische ISSN: 1756-9966

Neu im Fachgebiet Onkologie

15.01.2021 | COVID-19 | Nachrichten

Newsletter bestellen

Bildnachweise

Mail Icon II

The perfect personalized cancer therapy: cancer vaccines against neoantigens

Abstract

In Corona-Zeiten: Wie gut lassen sich Krebskranke per Telemedizin betreuen?

Wie beeinträchtigt Schmerz den Alltag von Krebsüberlebenden?

Akute myeloische Leukämie: Vier Zyklen ohne Überlebensvorteil

Mit dem Zweitbefund Diagnose- und Therapiefehler vermeiden

Newsletter

Springer Medizin

Abstract

Weitere Artikel der Ausgabe 1/2018

MNAT1 is overexpressed in colorectal cancer and mediates p53 ubiquitin-degradation to promote colorectal cancer malignance

The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model

Long non-coding RNA UFC1 promotes gastric cancer progression by regulating miR-498/Lin28b

Upregulation of lactate-inducible snail protein suppresses oncogene-mediated senescence through p16INK4a inactivation

Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway

CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma

Neu im Fachgebiet Onkologie

In Corona-Zeiten: Wie gut lassen sich Krebskranke per Telemedizin betreuen?

Wie beeinträchtigt Schmerz den Alltag von Krebsüberlebenden?

Akute myeloische Leukämie: Vier Zyklen ohne Überlebensvorteil

Mit dem Zweitbefund Diagnose- und Therapiefehler vermeiden

Newsletter